Patent Grant
10548920
The present invention relates to methods and systems for administering a pharmaceutical gas to a patient and, more particularly, to methods and systems for introducing carbon monoxide CO or nitric oxide NO to a patient in a predetermined quantity.
The normal or conventional way of giving a pharmaceutical drug to a patient is to prescribe the dose based on the quantity of drug (usually in weight) per unit weight of the patient (e.g. mg/Kg) with the dose being specified to be delivered over a period of time or being repeated at specified intervals of time. This allows the user to control the quantity of drug and ensures the quantity of drug being delivered is in proportion to the patient's size. This is to reduce the patient to patient variability in response to the drug due to the size of the patient i.e. a 7 Kg baby will not get the same quantity of drug as a 80 Kg adult.
In recent times there have been a number of gases which have been shown to have pharmaceutical action in humans and animals. Examples include Nitric Oxide (NO) Zapol et al U.S. Pat. No. 5,485,827 and more recently Carbon Monoxide (CO) Otterbein et al (U.S. Published Patent Application No. 2003/0219496). In the Otterbein patent application, CO is described as having a pharmacological action in a number of medical conditions including ileus and vascular disease.
In these cases, the carbon monoxide gas needs to be delivered to the patients alveoli where it can move across the alveolar membrane and into the blood stream where its action can take effect. The current dosing used in these cases is for the patient to breath at a specified concentration of CO in ppm for a specified period of time. Accurate dosing of CO for these treatments is important as CO reacts with the hemoglobin in the blood to form carboxyhemoglobin which means the hemoglobin is no longer able to carry oxygen to the tissues of the body. If too much CO is given, the patient may exhibit the toxic effects of CO for which it is usually known.
There is a tight window for CO delivery between the therapeutic level and the level that causes carboxyhemoglobin above safe levels. Up until now CO has been delivered as a constant concentration in the gas breathed by the patient/animal for a specified period of time. For example in reference 3 of the Otterbein publication, (Example 2 pg 13) the therapeutic dose delivered to mice for the treatment of ileus was 250 ppm of CO for 1 hour.
However, this method of dosing CO can be associated with large variability in the actual dose being delivered to the animal/humans alveoli. This variability is because the quantity of CO being delivered to the animal/patient is dependent on a number of variables including, but not limited to, the patients tidal volume, respiratory rate, diffusion rate across the alveolar and ventilation/perfusion (V/Q) matching.
The amount of CO delivered into a patient's alveoli can be determined by the ideal gas law as shown in the following equation:
N=PV/(RuT) (1)
Where: N is the number of moles of the gas (mole) P is the absolute pressure of the gas (joule/m3) V is the volume of the particular gas (m3), Ru is the universal gas constant, 8.315 joule/mole-K and T is the absolute temperature (K).
If we assume atmospheric pressure (101,315 joule/m3) and 20° C. (293 K) as the temperature and we express the volume in mL (10−6 m3), then equation (1) reduces to:
N=4.16×10−5V (moles) (2)
Equation (2) can be used to calculate the number of moles of gas delivered to a patient's alveolar volume over a period of time when given a specified concentration by using the following equation:
NCO=RR·t·CCO·10−6·4.16×10−5Va (3)
Where; CCO is the concentration of CO (ppm), Va is the alveolar volume (mL), RR is the respiratory rate (BPM) and t is the time in minutes.
For example, if the CO dose for ileus in humans was 250 ppm of CO for one hour (60 minutes), the alveolar volume is 300 mL and the patients respiratory rate is 12 breaths per minute (bpm) then the amount of CO gas in moles delivered to the patients alveoli over that period would be:
NCO=12·60·250·10−6·4.16×10−5·300=2.25×10−3 moles
This can be converted into the mass of drug delivered (MCO) using the gram molecular weight of CO which is 28 as shown in the following equation:
MCO=NCO·28=63×10−3 g=63 mg (4)
However, although this works for a given set of assumptions, a spontaneous patient's respiratory rate can vary widely from perhaps 8 to 20 breaths per minute depending on circumstances and the patient's alveolar volume per breath can also vary significantly from say 200 to 400 mL depending on the metabolic need. These variables can have a dramatic effect on the amount of gaseous drug being delivered to the patient over the same period of time. For instance, if the patients respiratory rate was 8 bpm and the alveolar volume was 200 mL, the CO dose delivered to the patients alveoli would have been 27.8 (mg). Likewise if the patients respiratory rate was 20 bpm and the alveolar volume was 400 mL, then the dose delivered to the patients alveoli would have been 139.2 (mg) thus representing a five-fold difference in the amount of drug being delivered.
This means, in the example of CO, the quantity of gaseous drug a patient gets as measured in grams could vary substantially depending on the patient's ventilation pattern. For a dose based on constant concentration and time, the effect of these variables could mean that an individual patient could get significantly higher or lower doses of CO in grams and this could result in either high unsafe levels of carboxyhemoglobin or doses too low to be effective. Although not all the gaseous drug delivered to the alveoli will be taken up by the body's bloodstream (due to variables such as cardiac output and the diffusion coefficient of the gas) controlling the amount delivered to the alveoli takes away a major source of variability.
In addition, there is a need to administer NO to a patient in a predetermined quantity as described in “Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease”, Nature Medicine, Volume 8, Number 12, December 2002, pages 1383 et seq. This paper describes the use of inhaled NO to react with cell free hemoglobin to form plasma methemoglobin and so reduce the ability of the cell free hemoglobin in the plasma to consume endogenously produced NO (FIG. 5, page 1386). The quantity of NO delivered to the patient blood needs to be equivalent to the amount of cell free hemoglobin that is in the patients plasma. The amount of NO delivered to a sample of sickle cell patients was 80 ppm of NO for 1.5 hours. However, there was variability in the amount of methemoglobin produced in individual patients as shown by the error bars on
Accordingly, it would be advantageous to have a system and method of introducing pharmaceutical gases (such as carbon monoxide and nitric oxide) that allows for the precise control of a known quantity of the pharmaceutical gas to be delivered to the patients alveoli and which is not subject to change based on the patients respiratory patterns.
Accordingly, the present invention relates to a system and method for administering a pharmaceutical gas, such as carbon monoxide and nitric oxide, that allows a clinician to determine and control the desired quantity of the gas to be delivered to the patient. The method determines the desired quantity of the pharmaceutical gas to be administered to the patient and then administers the desired quantity of the pharmaceutical gas irrespective of the patients respiratory patterns. If the prescription is specified as a total quantity of drug, then the method terminates the administration of the pharmaceutical gas when the desired total quantity has been administered to the patient.
Thus, by the method of the present invention, the amount of the pharmaceutical gas is delivered to the patient as a known desired quantity and that known desired quantity can be expressed in various units of measurement, such as, but not limited to, the weight of drug in micrograms (μg), milligrams (mg), grams (g) etc., the moles of drug in nanomoles (nM), micromoles (μM), millimoles (mM) moles (M) etc, or the volume of drug, at a known concentration or partial pressure, in microliters (μL), milliliters (mL), liters (L) etc. The desired quantity of the pharmaceutical gas can also be expressed as an amount per unit of time for a period of time such as mg/hour for 2 hours.
The invention also includes a system for administering a pharmaceutical gas, such as carbon monoxide or nitric oxide, and the system includes an inlet means that can be connected to the source of the pharmaceutical gas and deliver the gas to a patient by means of a patient device. That patient device can be any device that actually introduces the pharmaceutical gas into the patient such as a nasal cannula, endrotracheal tube, face mask or the like. There is also a gas control system that controls the introduction of the quantity of a pharmaceutical gas from the gas source through the patient device. Again, therefore, the system provides a known quantity of gas to the patient.
As such, the present invention allows a user to set a desired quantity of gaseous drug to be delivered to a patient's alveoli and for the system to then deliver that gaseous drug over multiple breaths until the prescribed amount has been delivered.
As a further embodiment, the system and method may simply provide an alarm, visual and/or audible, to alert the user when the predetermined total quantity of the pharmaceutical gas has been administered to the patient and not actually terminate that administration. As such, the user is warned that the total predetermined desired quantity administered over the plurality of breaths has now been delivered to the patient so that the user can take the appropriate action, including a closer monitoring of the patient.
These and other features and advantages of the present invention will become more readily apparent during the following detailed description taken in conjunction with the drawings herein.
In the following detailed description, CO is used as the pharmaceutical gas but the description can also be valid for NO. Referring now to
The means for determining the desired quantity of CO to be delivered is by means of a setting control including an input setting knob 12 with the set amount being shown on the setting display 8. The units shown in
The front panel 10 also has a monitor display 6 which can display total dose of CO (mg) to be delivered (shown at 16) as calculated for multiplying the dosage/kg by the patients ideal body weight in kg.
Once the desired quantity of gaseous drug has been set on the device the system then determines the amount of pharmaceutical gas that is to be delivered in each breath and the amount of time and/or the number of breaths that it will take to deliver the total desired quantity of drug. The monitor display 6 can also display a running total of the delivered dose of CO (mg) (shown at 17) as it is delivered to the patient so the user can monitor the progress of the treatment. This can be updated each breath as more pharmaceutical gas is delivered.
As stated, the units illustrated in
Referring to
Also, as in
As can be appreciated,
Once the desired quantity of gaseous drug has been set on the device, the gas control system can then determine the amount of pharmaceutical gas to be delivered in each breath and the amount of time and/or the number of breaths that it will take to deliver the desired quantity of pharmaceutical gas.
There are a number of different approaches that the gas control system can use to determine the amount per breath and how long to deliver that dose so the desired quantity of pharmaceutical gas is delivered independent of the respiratory pattern of the patient:
a) The user can set the quantity of pharmaceutical gas to be delivered during each breath (MCO breath) and the gas control system calculates the number of breaths (nbreaths) which will be required to deliver the total quantity of pharmaceutical gas (MCO) i.e.
nbreaths=MCOMCO breath (5)
Once the total number of breaths (nbreaths) required has been determined the value can be displayed on the front panel 12 by means of display 16 to inform the user of the number of breaths.
b) The user can set the number of breaths (nbreaths) that will administer the total quantity of the pharmaceutical gas and the system calculates the amount per breath (MCO breath) to be delivered.
MCO breath=MCO/nbreaths (mg) (6)
Once the amount per breath (MCO breath) to be delivered has been determined, the value can be displayed on the front panel 10 to inform the user of the amount.
(c) The user could set the time duration for which the treatment is to be delivered over. The amount per breath would then be determined by calculating the quantity per minute and then, by monitoring the patients respiration rate in breaths per minute, the amount of breath can be calculated. This calculation can be repeated after every breath so any changes in the patients respiratory rate does not affect the overall quantity of gaseous drug being delivered.
d) If the desired quantity of pharmaceutical gas was entered as a dose per Kg of the patient's ideal body weight (μg/kg) along with the patient's ideal body weight (Kg) then the amount per breath (MCO breath) can be determined as a function of the patient's ideal body weight (IBW), the set dose per kilogram (Mkg) and the patient's monitored respiratory rate (RR) or combinations thereof;
MCO breath=f (IBW, M_sub_kg, RR) and the number of breaths can then be calculated as;
nbreaths=MCO/MCO breath (7)
Once the amount per breath (MCO breath) and the number of breaths (nbreaths) required to be delivered has been determined, the values can be displayed on the front panel 10 to inform the user of the amounts the device has selected.
e) Instead of the ideal body weight (IBW) of the patient, the height and sex of the patient could be entered (which is how IBW is determined).
f) If the desired quantity of pharmaceutical gas per unit of time is entered into the device, then the device can calculate the quantity per breath to be delivered to the patient based on the current monitored respiratory breath rate (as determined by the breath trigger sensor). This quantity per breath can be recalculated after every breath when new information on the respiratory rate is available to ensure the quantity per unit of time is maintained even if the patient respiratory breath pattern changes over time.
g) There are also other ways of varying the quantity of pharmaceutical gas delivered per breath to ensure the quantity per unit of time is maintained even if the patients respiratory rate changes. Another example is where the device has two different amounts of delivery per breath, a high amount and a low amount. The device chooses which one to use based on the calculated quantity per unit of time being delivered over the past number of breaths. If the amount per unit of time is greater than required, it uses the low amount per breath until the situation corrects itself; likewise, if the quantity per unit of time is running low, then the unit switches to the high amount per breath.
The device can also have programmed limits which restrict the maximum and minimum values that can be selected for MCO breath so that the system doesn't select inappropriately too high or too low values. These limits can be set to vary based on the patient's ideal body weight, or other indicator of the patient size such as the patient's height, or the respiratory rate of the patient.
The aforesaid information is sufficient for the system of the present invention to deliver the dose to the patient and to determine the amount per breath, time of administration or other parameter in order to commence the administration of CO and to terminate that administration when the user set quantity of the pharmaceutical gas has been delivered to the patient.
Turning now to
With the
Accordingly, from the supply tank 20, there is a tank pressure gauge 21 and a regulator 23 to bring the tank pressure down to the working pressure of the gas delivery system 22. The pharmaceutical gas enters the gas delivery system 22 through an inlet 24 that can provide a ready connection between that delivery system 22 and the supply tank 20 via a conduit. The gas delivery system 22 has a filter 25 to ensure no contaminants can interfere with the safe operation of the system and a pressure sensor 27 to detect if the supply pressure is adequate and thereafter includes a gas shut off valve 26 as a control of the pharmaceutical gas entering the deliver system 22 and to provide safety control in the event the delivery system 22 is over delivering the pharmaceutical gas to the patient. In the event of such over delivery, the shut off valve 26 can be immediately closed and an alarm 42 sounded to alert the user that the gas delivery system has been disabled. As such, the shut off valve 26 can be a solenoid operated valve that is operated from signals directed from a central processing unit including a microprocessor.
Downstream from the shut off valve 26 is a flow control system that controls the flow of the pharmaceutical gas to the patient through the patient device 18. In the embodiment shown, the flow control system comprises a high flow control valve 28 and a low control valve 30 and just downstream from the high and low flow control valves 28, 30, respectively, are a high flow orifice 32 and a low flow orifice 34 and the purpose and use of the high and low flow valves 28, 30 and the high and low flow orifices 32, 34 will be later explained. A gas flow sensor 36 is also located in the flow of pharmaceutical gas to the patient device 18 and, as shown, is downstream from the flow control system, however, the gas flow sensor 36 may alternatively be located upstream of the flow control system.
Next, there is a patient trigger sensor 38. When the patient breathes in during inspiration it creates a small sub atmospheric pressure in the nose or other area where the patient device 18 is located, and hence in the patient device 18 itself. The patient trigger sensor 38 detects this pressure drop and provides a signal indicative of the start of inspiration of the patient. Similarly, when the patient breathes out there is a positive pressure in the patient device 18 and the patient trigger sensor 38 detects that positive pressure and provides a signal indicative of the beginning of expiration. This allows the patient trigger sensor 38 to determine not only the respiratory rate of the patient but also the inspiratory and expiratory times.
Finally there is a CPU 40 that communicates with the patient trigger sensor 38, the high and low flow valves 28, 30, the gas shut off valve 26 and other components in order to carry out the purpose and intent of the present invention. The CPU 40 may include a processing component such as a microprocessor to carry out all of the solutions to the equations that are used by the gas delivery system 22 to deliver the predetermined quantity of the pharmaceutical gas to a patient. The CPU 40 is connected to the front panel 10 where the user can enter settings and monitor therapy.
The use of the delivery system 22 of the present invention for spontaneous breathing can now be explained. When the delivery system 22 detects by means of the patient trigger sensor 38 that inspiration has started, there is a signal that is provided to the CPU 40 to deliver a dose of a pharmaceutical gas (MCO breath) into the patient's inspiratory gas flow, preferably during the first ½ of the inspiratory cycle. This amount per breath has been determined based on the desired quantity of pharmaceutical gas that has been set on the system and the calculations made in a) to g) described earlier.
The actual volume of gas delivered during the breath depends on the concentration of the pharmaceutical gas in the carrier gas that is supplied by the supply tank 20. A typical source concentration (CCO) for CO would be 3000 ppm (range 500 to 5000). The volume of source gas (Vd) per breath to provide a dose per breath (MCO breath) when the source of CO is 3000 ppm is given by the following equation, combining equations 2, 3, 4 and 6;
Vd=MCO breath/(28·CCO·4.16×10−11) (8)
Given that MCO=60×10−3 (g), CCO=3000 (ppm), nbreaths=600, then Vd=28.6 (mL).
To deliver the volume of source gas per breath (Vd), that is, the pharmaceutical gas and the carrier gas, the delivery system 22 opens a flow control valve, such as high flow valve 28 or low flow valve 30 to allow the gas to flow to the patient until the volume per breath (Vd) has been delivered. The presence of the high flow orifice 32 and the low flow orifice 36 limits the flow of gas to a fixed set level during the period that the high or low flow valves 28, 30 are open so the delivery system 22 can determine the period of time the high or low flow valves 28, 30 should be open to deliver the volume per breath (Vd) required. Also, as another option, the flow can be determined by the gas flow sensor 36 to monitor the gas flow to the patient device 18 and thus to the patient and can shut off the appropriate high or low flow control valve 28, 30 when the desired predetermined quantity of pharmaceutical gas dose has been delivered to the patient.
As can be seen, to provide enough range to cover all the possible doses, the use of multiple flow valves, that is, the high flow valve 28 and the low flow valve 30 along with corresponding multiple orifices, high flow orifice 32 and low flow orifice 34, can be used in parallel so as to provide high and low ranges of gas flow. For instance, the low flow gas flow through the low flow valve 30 could be set to 1 L/min and the high flow gas flow through the high flow control valve 28 could be set to 6 L/min. The flow range of the particular gas flow valve is selected to ensure that the volume of gas per breath (Vd) can be delivered to the patient in at least ½ the inspiratory time.
As an example, if the patient was breathing at 12 breaths per minute and had an I:E ratio of 1:2 then the inspiratory time would be 1.66 seconds and half that would be 0.83 seconds.
The time (t) taken to deliver a Vd of 28 mL can be calculated as follows.
t=Vd60/(Q·1000)(secs) (9)
When Q (the flow of gas when the high flow valve 28 is open)=6 L/mins t=0.28 (secs).
That time is therefore well within ½ the inspiratory time allowed of 0.83 seconds.
The delivery system 22 can also include monitoring and alarm features to alert the user if the delivery system 22 is not working correctly. Those alarm conditions can be determined by the CPU 40 and the alarm 42 activated to alert the user to the particular fault condition. The alarm 42 can be audible, visual or both and the alarm conditions can be any one or all of the following: No breath detected Low source gas pressure Inaccurate delivery of the volume per breath (Vd) Over delivery of the volume per breath (Vd) Under delivery of the volume per breath (Vd)
Under certain conditions, such as when the delivery system 22 is over delivering the pharmaceutical gas, the CPU 40 may signal the gas shut off valve 26 and immediately cease any further delivery of the pharmaceutical gas and the alarm 42 also activated.
The use of the alarm 42 can also be an alternative to actually shutting off the supply of the pharmaceutical gas to a patient when the predetermined desired quantity of pharmaceutical gas has been fully delivered to the patient. In such case, as an alternative to ceasing the further supply of the pharmaceutical gas to the patient, the delivery system 22 may, by means of the CPU 40, activate the alarm 42 to alert the user that the total predetermined desired quantity of the pharmaceutical gas has been delivered. The user can then determine whether to manually deactivate the delivery system 22 or continue the delivery of the pharmaceutical gas under more watchful control of the patient's status.
Turning now to
The high and low flow control valves 28 and 30 control the flow of the pharmaceutical gas through the gas delivery system 44 and, the high and low flow valves 28, 30 operate as described with respect to the
Again there is a gas flow sensor 36 and a patient trigger sensor 66, both of which communicate with the CPU 40. With this embodiment, however, the pharmaceutical gas is carried through an outlet conduit 70 to a patient device 72 that also receives the breathing gas from the ventilator 46. As such, the ventilator 46 delivers a flow of gas through the inspiratory limb 74 and gas is returned to the ventilator 46 through the expiratory limb 76.
The flow of gas from the ventilator 46 is thus supplemented by the flow of pharmaceutical gas from the gas delivery system 44 where that gas is mixed at or proximate to the patient device 72 for introduction into the patient 78. Since all of the pharmaceutical gas is still delivered to the patient over the plurality of breaths, basically the CPU 40 can carry out the same determination of flows and the like as explained with respect to the
For instance, when the ventilator 46 provides gas flow to a patient during inspiration, it causes a positive pressure in the breathing circuit. The positive pressure is conducted through the outlet conduit 70 and is detected by the patient trigger sensor 66 and is recognized as the start of inspiration. This is the opposite to the embodiment of
Those skilled in the art will readily recognize numerous adaptations and modifications which can be made to the pharmaceutical gas delivery system and method of delivering a pharmaceutical gas of the present invention which will result in an improved method and system for introducing a known desired quantity of a pharmaceutical gas into a patient, yet all of which will fall within the scope and spirit of the present invention as defined in the following claims. Accordingly, the invention is to be limited only by the following claims and their equivalents.
This application is a continuation under 35 U.S.C. § 120 of U.S. patent application Ser. No. 13/778,596, filed Feb. 27, 2013, which is a continuation of U.S. patent application Ser. No. 13/536,272, filed Jun. 28, 2012, now U.S. Pat. No. 8,408,206, issued Apr. 2, 2013, U.S. patent application Ser. No. 13/287,663, filed Nov. 2, 2011, now U.S. Pat. No. 8,517,015, issued Aug. 27, 2013, and U.S. patent application Ser. No. 13/284,433, filed Oct. 28, 2011, now U.S. Pat. No. 8,397,721, issued Mar. 19, 2013, which are continuations of U.S. patent application Ser. No. 12/430,220, filed Apr. 27, 2009, now U.S. Pat. No. 8,091,549, issued Jan. 10, 2012, which is a continuation of U.S. patent application Ser. No. 11/231,554, filed Sep. 21, 2005, now U.S. Pat. No. 7,523,752, issued Apr. 28, 2009, the entire disclosures of which are hereby incorporated by reference herein.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4686974 | Sato et al. | Aug 1987 | A |
| 5485827 | Zapol et al. | Jan 1996 | A |
| 5558083 | Bathe et al. | Sep 1996 | A |
| 5713349 | Keaney et al. | Feb 1998 | A |
| 5732693 | Bathe et al. | Mar 1998 | A |
| 5752504 | Bathe | May 1998 | A |
| 5839433 | Higenbottam | Nov 1998 | A |
| 5885621 | Head et al. | Mar 1999 | A |
| 5918596 | Heinonen | Jul 1999 | A |
| 6089229 | Bathe et al. | Jul 2000 | A |
| 6109260 | Bathe | Aug 2000 | A |
| 6125846 | Bathe et al. | Oct 2000 | A |
| 6164276 | Bathe et al. | Dec 2000 | A |
| 6581592 | Bathe et al. | Jun 2003 | B1 |
| 6739336 | Jalde et al. | May 2004 | B1 |
| 6786217 | Stenzler | Sep 2004 | B2 |
| 6880556 | Uchiyama et al. | Apr 2005 | B2 |
| 6955171 | Figley et al. | Oct 2005 | B1 |
| 6962154 | Krebs | Nov 2005 | B2 |
| 7127278 | Melker et al. | Oct 2006 | B2 |
| 7290544 | Sarela et al. | Nov 2007 | B1 |
| 7331343 | Schmidt et al. | Feb 2008 | B2 |
| 7370651 | Holder | May 2008 | B2 |
| 7516742 | Stenzler et al. | Apr 2009 | B2 |
| 7523752 | Montgomery et al. | Apr 2009 | B2 |
| 7687079 | Otterbein et al. | Mar 2010 | B2 |
| 7690378 | Turcott | Apr 2010 | B1 |
| 7861717 | Krebs | Jan 2011 | B1 |
| 8091549 | Montgomery et al. | Jan 2012 | B2 |
| 8282966 | Baldassarre et al. | Oct 2012 | B2 |
| 8291904 | Bathe et al. | Oct 2012 | B2 |
| 8293284 | Baldassarre et al. | Oct 2012 | B2 |
| 8397721 | Montgomery et al. | Mar 2013 | B2 |
| 8408206 | Montgomery et al. | Apr 2013 | B2 |
| 8431163 | Baldassarre et al. | Apr 2013 | B2 |
| 8573209 | Bathe et al. | Nov 2013 | B2 |
| 8573210 | Bathe et al. | Nov 2013 | B2 |
| 8776794 | Bathe et al. | Jul 2014 | B2 |
| 8776795 | Bathe et al. | Jul 2014 | B2 |
| 8795741 | Baldassarre | Aug 2014 | B2 |
| 8846112 | Baldassarre | Sep 2014 | B2 |
| 20020155166 | Choi et al. | Oct 2002 | A1 |
| 20030009127 | Trescony et al. | Jan 2003 | A1 |
| 20030219496 | Otterbein et al. | Nov 2003 | A1 |
| 20030219497 | Otterbein et al. | Nov 2003 | A1 |
| 20040228930 | Billiar et al. | Nov 2004 | A1 |
| 20050039740 | Fritz et al. | Feb 2005 | A1 |
| 20050076907 | Stenzler | Apr 2005 | A1 |
| 20060207594 | Stenzler et al. | Sep 2006 | A1 |
| 20070144518 | Acker et al. | Jun 2007 | A1 |
| 20080029093 | Stenzler et al. | Feb 2008 | A1 |
| 20100089392 | Fine | Apr 2010 | A1 |
| 20100175695 | Jamison | Jul 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 2368059 | Mar 2000 | CN |
| 2439288 | Jul 2001 | CN |
| 0659445 | Jun 1995 | EP |
| 0960629 | Dec 1999 | EP |
| 0960630 | Dec 1999 | EP |
| 10179742 | Jul 1998 | JP |
| 2000024110 | Jan 2000 | JP |
| 2002143305 | May 2002 | JP |
| 9737644 | Oct 1997 | WO |
| 0121239 | Mar 2001 | WO |
| 2004004817 | Jan 2004 | WO |
| Entry |
|---|
| European Search Report in EP 06 80 3413, dated Jul. 18, 2011, 6 pages. |
| Extended EP Search Report in EP13172342.1-1662, dated Aug. 30, 2013, 7 pages. |
| Final Office Action in U.S. Appl. No. 13/778,596, dated Oct. 19, 2015, 8 pages. |
| INOmax DS (Delivery System): Operation Manual (800 ppm INOmax (nitric oxide) for Inhalation), Ikaria, Inc., 2010, 112 pages. |
| INOmax Label, (Nitric Oxide) for Inhalation, 2009, 9 pages, 2009. |
| INOmax Label, Nitric Oxide Gas, INO Therapeutics 2013, 2 pages, 2013. |
| INOvent delivery system—Operation and Maintenance Manual, Feb. 8, 2000, 180 pgs. |
| INOmax DSIR Operation Manual (Delivery System) (800 ppm INOmax (nitric oxide) for inhalation), 2012, 136 pages. |
| International Written Opinion in PCT/US2006/35450, dated Aug. 7, 2007, Aug. 7, 2007, 5 pages. |
| “Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation”, American Academy of Pediatrics, 2004, 20 pages. |
| “Nitric Oxide”, CDC—NIOSH Pocket Guide to Chemical Hazards—Nitric oxide http://www.edc.gov/niosh/npg/npgd0448.html, Apr. 13, 2011, 2 pages. |
| Non-Final Office Action in U.S. Appl. No. 13/287,663, dated Nov. 20, 2012, 11 pages. |
| Non-Final Office Action in U.S. Appl. No. 13/331,807, dated Apr. 21, 2014, 13 pages. |
| Non-Final Office Action in U.S. Appl. No. 13/536,272, dated Sep. 10, 2012, 9 pages. |
| Non-Final Office Action in U.S. Appl. No. 13/942,049, dated Sep. 27, 2013, 10 pages. |
| Non-Final Office Action in U.S. Appl. No. 13/942,115 dated Aug. 28, 2013, 6 pages. |
| Non-Final Office Action in U.S. Appl. No. 13/942,115, dated Sep. 18, 2013, 9 pages. |
| Non-Final Office Action in U.S. Appl. No. 13/942,136 dated Aug. 27, 2013, 6 pages. |
| Notice of References Cited, U.S. Appl. No. 12/430,220, dated Mar. 8, 2011, 1 page. |
| Notice of References Cited, U.S. Appl. No. 11/231,554, dated Apr. 3, 2008, 1 page. |
| International Preliminary Report on Patentability in PCT/US2006/035450, dated Mar. 26, 2008, 6 pages. |
| U.S. 1449, U.S. Appl. No. 11/231,554, filed Nov. 13, 2007, 2 pages. |
| U.S. 1449, U.S. Appl. No. 11/231,554, filed Sep. 21, 2005, 3 pages. |
| Using the INOpulse DS Subject Guide, 2012, 50 pages. |
| Air Products & Chemicals, Inc., “Nitric Oxide”, Material Safety Data Sheet, 1998, 6 pages. |
| Ashutosh, Kumar, et al., “Use of nitric oxide inhalation in chronic obstructive pulmonary disease”, Thorax 55, 2000, 109-113. |
| Baigorri, M.D., Francisco, et al., “Inhaled nitric oxide does not improve cardiac or pulmonary function in patients with an exacerbation of chronic obstructive pulmonary disease”, Crit. Care Med., vol. 27, No. 10, 1999, 2153-2158. |
| Blanch, L., et al., “Hemodynamic and gas exchange responses to inhalation of nitric oxide in patients with the acute respiratory distress syndrome and in hypoxemic patients with chronic obstructive pulmonary disease”, Intensive Care Med 23, 1997, 51-57. |
| Fellahi, Jean-Luc, et al., “Inhaled Nitric Oxide-induced Closure of a Patent Foramen Ovale in a Patient with Acute Respiratory Distress Syndrome and Life-threatening Hypoxemia”, Anesthesiology 83, 1995, 635-638. |
| Germann, Peter, et al., “Addition of Nitric Oxide to Oxygen Improves Cardiopulmonary Function in Patients with Severe COPD”, Chest 114, 1998, 29-35. |
| Higenbottam, Tim W., et al., “Use of nitric oxide inhalation in COPD”, Thorax 55, 2000, 1 page. |
| Katayama, Yoshihiko, et al., “Inhaled nitric oxide and arterial oxygen tension in patients with chronic obstructive pulmonary disease and severe pulmonary hypertension”, Thorax 52, 1997, 120-124. |
| Lu, M.D., Qin, et al., “Dose-Response Curves of Inhaled Nitric Oxide with and without Intravenous Almitrine in Nitric Oxide-responding Patients with Acute Respiratory Distress Syndrome”, Anesthesiology 83, 1995, 929-943. |
| Melsom, M.N., et al., “Low concentrations of inhaled nitric oxide do not improve oxygenation in patients with very severe chronic obstructive pulmonary disease”, Acta Anaesthesiol Scan 51, 2007, 559-564. |
| Mesa Specialty Gases & Equip., “Nitric Oxide—Material Safety Data Sheet”, Nitric Oxide Balance Nitrogen, Jan. 1, 2004, 2 pgs. |
| Miller, Chris, et al., “Gaseous nitric oxide bactericidal activity retained during intermittent high-does short duration exposure”, Nitric Oxide 20, 2009, 16-23. |
| Miller, Andrew, et al., “Validation of a Simplified, Portable Cardiopulmonary Gas Exchange System for Submaximal Exercise Testing”, The Open Sports Medicine Journal, 4, 2010, 34-40. |
| Moinard, Jean, et al., “Effect of Inhaled Nitric Oxide on Hemodynamics and Va/Q Inequalities in Patients with Chronic Obstructive Pulmonary Disease”, American Journal of Respiratory and Critical Care Medicine, vol. 149, 1994, 1482-1487. |
| Puybasset, L., et al., “Inhaled nitric oxide in acute respiratory failure: dose-response curves”, Intensive Care Med 20, 1994, 319-327. |
| Roger, Nuria, et al., “Nitric Oxide Inhalation During Exercise in Chronic Obstructive Pulmonary Disease”, Am J. Respir Crit Care Med 156, 1997, 800-806. |
| Vonbank, K., et al., “Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD”, Thorax 58, 2003, 289-293. |
| Yoshida, M., et al., “The effect of low-dose inhalation of nitric oxide in patients with pulmonary fibrosis”, Eur. Respir. J. 10, 1997, 2051-2054. |
| Number | Date | Country | |
|---|---|---|---|
| 20160271168 A1 | Sep 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13778596 | Feb 2013 | US |
| Child | 15167048 | US | |
| Parent | 13536272 | Jun 2012 | US |
| Child | 13778596 | US | |
| Parent | 13287663 | Nov 2011 | US |
| Child | 13536272 | US | |
| Parent | 13284433 | Oct 2011 | US |
| Child | 13287663 | US | |
| Parent | 12430220 | Apr 2009 | US |
| Child | 13284433 | US | |
| Parent | 11231554 | Sep 2005 | US |
| Child | 12430220 | US |
